Navigation Links
Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
Date:7/23/2008

se in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response. Dendreon is also developing an orally-available small molecule called Trp-p8 that could be applicable to multiple types of cancer as well as benign prostatic hyperplasia. The Company has its headquarters in Seattle, Washington and is traded on the Nasdaq Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com.

Except for historical information contained herein, this news release contains forward-looking statements that are subject to risks and uncertainties surrounding the efficacy of PROVENGE to treat men suffering from prostate cancer, risks and uncertainties surrounding the presentation of data to the FDA and approval of product applications by the FDA and risks and uncertainties inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics. Factors that may cause such differences include risks related to our limited operating history, risks associated with completing our clinical trials, the risk that the safety and/or efficacy results of existing clinical trials or from additional clinical trials for PROVENGE will not support approval for a biologics license, the risk that the FDA may interpret data differently than we do or require more data or a more rigorous analysis of data than expected, the risk that the FDA will not approve a product for which a biologics license has been applied, the risk that the results of a clinical trial for PROVENGE or other product may not be indicative of results obtained in a later clinical trial, risks that we may lack the financial resources and access to capital to fund required clinical trials or commercialization of PROVENGE, our dependence on the efforts of third pa
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
8. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
9. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
10. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
11. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... 16, 2014 Astellas announced today it ... Communications & Advocacy, Urology in the Americas. Noland will ... Advocacy Margaret Long. In this role, Noland will be ... patient and advocacy organizations, as well as collaborating ... initiatives. Noland,s appointment is the latest phase in ...
(Date:9/16/2014)... 2014 /PRNewswire-iReach/ -- Dan York has been ... of the RTD ® Advanced Wound Care Dressing, ... sales presence in the U.S. Under York,s leadership, GWM ... field sales representatives in new sales territories that will ... add up to 20 sales representatives in major metropolitan ...
(Date:9/16/2014)... DIEGO , Sept. 16, 2014  Denovo ... enzastaurin, a late-stage oncology drug, from Eli Lilly ... to develop, manufacture and commercialize enzastaurin globally, including ... data, and information. Lilly developed ... Phase 2 and Phase 3 clinical trials for ...
Breaking Medicine Technology:Christy Noland to Lead Urology Advocacy and Communications for Astellas 2GWM Products, LLC, announces U.S. market expansion. Dan York added as Director of Sales as part of nationwide growth initiative. 2Denovo Biopharma Acquires Late-Stage Oncology Drug From lilly For Development As A Personalized Medicine 2
... 2011 Reportlinker.com announces that a new market research ... Gastric Cancer Drug Discoveries: what the future holds ... Original analysis of the clinical potential ... candidates put into current market context Original ...
... 2011 Reportlinker.com announces that a new market research report ... Stent Market Outlook to 2016 http://www.reportlinker.com/p0483600/The-Drug-Eluting-Stent-Market-Outlook-to-2016.html ... DES market has seen tremendous growth since the introduction of ... on the release of clinical data that indicated a link ...
Cached Medicine Technology:Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 2Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 3Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 4Reportlinker Adds Gastric Cancer Drug Discoveries: what the future holds 5Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 2Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 3Reportlinker Adds the Drug-Eluting Stent Market Outlook to 2016 4
(Date:9/16/2014)... 2014 Keep that sexy decolletage as you ... neck. , "The Face Whisperer Neck & Decollete Cream ... Heshelow, founder of Sublime Beauty®. "It contains rich ingredients to ... and arnica." , A special ingredient is Argireline, known as ... rich anti-aging cream comes in an airless pump bottle, and ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Today, ... published new information on transitioning employees to individual ... with the Affordable Care Act (ACA) in full ... be steering some or all of their employees ... surprise. With guaranteed issue plans, coverage for pre-existing ...
(Date:9/16/2014)... the well-known wedding dress manufacturer and retailer, has unveiled ... Additionally, the firm has launched a promotion for its ... up to 62 percent off. , All ... won a lot of positive reviews for its high-quality ... big savings on many other items, including corset bridesmaid ...
(Date:9/16/2014)... 16th, 2014; San Francisco) In a healthcare ... weighed against potential benefit, a Yale study has ... less-aggressive radiation procedures on elderly women with early-stage ... presented at the 56th annual conference of the ... (Abstract 131: Evaluating National Practice in Radiotherapy for ...
(Date:9/16/2014)... Recently, iFitDress.com, one of the most famous dress suppliers ... evening gown collection. According to the company’s sales manager, ... (up to 69% off) at present. Additionally, all the company’s ... am a frequent caller of your site. I like your ... feel quite happy. All items are of good quality. I ...
Breaking Medicine News(10 mins):Health News:15% Off Face Whisperer® Neck & Decollete Cream Now from Sublime Beauty; Care For This Delicate Skin That Shows Age Quickly 2Health News:Zane Benefits Publishes New Information on Transitioning Employees to Individual Health Insurance 2Health News:New Elegant Evening Wear Assortment Released By UWDress.com 2Health News:iFitDress.com: One Shoulder Evening Gown Collection Unveiled Online 2
... a 60-cm-long sword that had been thrust through the nose ... ear, news reports said Wednesday. ,Ronnachai Tiemsanguan, 16, ... sword's removal from his face in an operation that took ... newspaper. ,Ronnachai received his sword wound Saturday when ...
... in the field of conducting tasks that involve spatial ... light turns green. , Researcher Eric Schumacher, ... Technology and colleagues, were surprised when they conducted MRI ... ,The researchers were testing the notion that areas ...
... suggests that ovarian cancer cells form by hijacking a ... Scientists at the Georgia Institute of Technology and the ... involved in the development of fallopian tubes and is ... ovarian tissue. The discovery not only provides a new ...
... Barbara, California – March 6, 2007 -- A team ... Berkeley and StrataGent// Life Sciences, of Los Gatos, California, ... to deliver protein drugs into the skin without the ... The research was published online today in the Proceedings ...
... It's already been established that type 2 diabetes increases the ... also a link between type 1 diabetes and this type ... but still, those with type 1 diabetes have a likelihood ... in non-diabetics. This is similar to the risk those with ...
... International Narcotics Control Board (INCB) – an independent body ... control// standards – is calling for the danger of ... ,In its annual report, the Vienna-based organisation ... drugs are not illegally manufactured or diverted from authorised ...
Cached Medicine News:Health News:Same Areas of the Brain Prepare for and Respond to a Stimulus, Say Experts 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 2Health News:Ovarian Cancer May Mimic Fallopian Tube Formation 3Health News:Researchers Design Pulsed Mircrojet System to Deliver Protein Drugs Without Pain or Bruising 2Health News:Flood of Fake Drugs Must Be Stopped, Warns UN 2
... The RapidPCP test is an immunochromatography ... It is,designed for qualitative determination of ... cut-off level of 25 ng/mL. This ... the point of care location,and is ...
... Rapid Opiate II Rapid Opiates is an ... is designed for qualitative determination of Opiates ... presence of morphine in human urine above ... This assay has not been evaluated in ...
... All of DOA Panel ... one step in vitro test. ... of drug substances in human ... not,been evaluated in the point ...
... an immunochromatography based one step in vitro ... THC and its metabolites in human urine,specimens. ... urine above a cut-off,level of 50 ng/mL ... been evaluated in the point of care,location ...
Medicine Products: